On Feb. 2, 2021, Mateon Therapeutics announced that its ARTI-19 trial, evaluating ARTIVeda / PulmoHeal against COVID-19 in India, had completed randomization of all 120 patients and final analysis is expected in March 2021.

Simultaneously, Mateon published positive interim data as preprint at medrxiv.org. ARTIVeda is the first Ayurvedic drug against COVID-19 through TGF-inhibition. ARTIVeda is expected to be effective through the entire infection cycle.